Tinygemsbreaks Kairos Pharma Ltd. (NYSE American: KAPA) Highlights Pipeline Expansion And Clinical Milestones In Mid-Year Shareholder Update

(MENAFN- Investor Brand Network) Kairos Pharma (NYSE American: KAPA) provided a mid-year 2026 update highlighting plans to expand its oncology pipeline through the proposed acquisition of worldwide rights to CL-741, a Phase 1-ready oral c-MET kinase inhibitor from Celyn Therapeutics targeting EGFR-mutated lung cancer and other cancers. The company said CL-741 would complement its existing portfolio, which includes ENV-105, KROS-201, KROS-102 and ENV-205. Looking ahead, Kairos expects to initiate a Phase 1 study of CL-741, advance ongoing clinical trials of ENV-105 in prostate cancer and non-small cell lung cancer, present data at scientific meetings and pursue pharmaceutical collaborations. The company also noted it has secured more than $8 million in non-dilutive funding to support development of its preclinical and clinical programs.

To view the full press release, visit

About Kairos Pharma, Ltd.

Based in Los Angeles, California, Kairos Pharma Ltd. ( NYSE American: KAPA ) is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. Kairos Pharma's lead candidate, ENV-105, is an antibody that targets CD105-a protein identified as a key driver of resistance and disease relapse in response to standard therapy. ENV-105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types. Currently, ENV-105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer aimed at addressing significant unmet medical needs. As of the date of this press release, ENV-105 has not been approved as safe or effective by the United States Food and Drug Administration or any other comparable foreign regulator.

NOTE TO INVESTORS: The latest news and updates relating to KAPA are available in the company's newsroom at

About TinyGems

TinyGems is a specialized communications platform with a focus on innovative small-cap and mid-cap companies with bright futures and huge potential. It is one of 75+ brands within the Dynamic Brand Portfolio IBN: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ; (2) article and editorial syndication to 5,000+ outlets ; (3) enhanced press release enhancement to ensure maximum impact ; (4) social media distribution via IBN to millions of social media followers ; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TinyGems is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, TinyGems brings its clients unparalleled recognition and brand awareness. TinyGems is where breaking news, insightful content and actionable information converge.

MENAFN04062026000224011066ID1111213049